What is the recommended initiation, dosing, administration, and titration protocol for insulin degludec (Tresiba) in an adult with type 1 or type 2 diabetes?

Insulin Degludec (Tresiba) Dosing Protocol

For Type 2 diabetes, start insulin degludec at 10 units once daily subcutaneously; for Type 1 diabetes, start at one-third to one-half of total daily insulin dose (or calculate 0.2-0.4 units/kg as total daily dose, with degludec comprising one-third to one-half). 1

Initial Dosing by Diabetes Type

Type 2 Diabetes (Insulin-Naïve)

• Start: 10 units once daily subcutaneously 1
• Can be administered at any time of day in adults (flexibility is a key advantage) 1
• Must be same time daily in pediatric patients 1

Type 1 Diabetes (Insulin-Naïve)

• Calculate total daily insulin: 0.2-0.4 units/kg body weight 1
• Degludec dose: One-third to one-half of this total 1
• Remainder: Short-acting insulin divided among meals 1
• Critical: Must use with short-acting insulin—degludec alone is insufficient for Type 1 diabetes 1

Switching from Other Insulins

Adults (Type 1 or Type 2)

• Start degludec at same unit dose as previous long/intermediate-acting insulin 1
• Unit-for-unit conversion 1

Pediatric Patients (≥1 year)

• Start at 80% of previous long/intermediate-acting insulin dose 1
• This dose reduction minimizes hypoglycemia risk in children 1

Titration Protocol

Increase dose by 2 units every 3-4 days to reach fasting plasma glucose goal without hypoglycemia 2. This is the evidence-based titration algorithm recommended by the 2025 ADA Standards 2.

Titration Guidelines:

• Frequency of adjustment: Every 3-4 days 2, 1
• Target: Individualized fasting plasma glucose goal 2
• Monitor adequacy at every visit 2
• Assess for signs of overbasalization (elevated bedtime-to-morning glucose differential, hypoglycemia, high glucose variability) 2

Hypoglycemia Management:

• If hypoglycemia occurs: Determine cause 2
• If no clear reason: Reduce dose by 10-20% 2
• For severe hypoglycemia, prescribe glucagon for emergencies 2

Administration Details

Available Formulations:

• U-100: FlexTouch pen (1-unit increments, max 80 units/injection) and 10 mL vial 1
• U-200: FlexTouch pen (2-unit increments, max 160 units/injection) 1
• No dose conversion needed between concentrations—the pen displays actual units 1

Administration Rules:

• Subcutaneous injection only—never IV or in insulin pumps 1
• Never dilute or mix with other insulins 1
• Never transfer from pen to syringe 1
• For pediatric patients requiring <5 units daily, use U-100 vial 1

Missed Dose Protocol:

• Adults: Inject during waking hours when discovered; ensure ≥8 hours between consecutive doses 1
• Pediatric patients: Contact provider for guidance; increase glucose monitoring until next scheduled dose 1

Key Clinical Advantages

The ultra-long half-life (approximately 25 hours) provides 3:

• Exceptionally flat pharmacokinetic/pharmacodynamic profile at steady state
• Flexible dosing in adults—can vary injection time day-to-day without compromising control 4
• Reduced nocturnal hypoglycemia compared to glargine and detemir 5, 6
• More consistent fasting glucose control 5, 6

Critical Warnings

Never share pens, needles, or syringes between patients—risk of blood-borne pathogen transmission 1

Contraindicated during hypoglycemic episodes 1

Monitor closely when changing injection sites, especially from areas of lipodystrophy or localized cutaneous amyloidosis to unaffected areas—sudden site changes can cause hypoglycemia 1

Dose adjustments needed with changes in physical activity, meal patterns, renal/hepatic function, or acute illness 1

When to Intensify Beyond Basal Insulin

If A1C remains above goal on optimized basal insulin 2:

• First: Add GLP-1 RA or dual GIP/GLP-1 RA if not already prescribed (consider fixed-ratio IDegLira) 2
• Then: Add prandial insulin—start with 4 units or 10% of basal dose at largest meal 2